Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism.
EHA Presentation Details
- Pharmacologic inhibition of cellular metabolic processes impacted by aging sensitize acute myeloid leukemia (AML) cells to the novel lipoate derivative CPI-613
-
- Date/Time: Saturday, June 16, 2018 from 17:30 - 19:30
- Type: Poster Presentation
- Location: Stockholmsmässan: Mässvägen 1, 125 80 Älvsjö, Sweden - Poster Area
- Abstract #: PS939
- Link to abstract
- Scheduled Presenters: Timothy S. Pardee, M.D., Ph.D., CMO of Rafael Pharmaceuticals, and Sanjeev Luther, President & CEO of Rafael Pharmaceuticals
- Analysis of Phase I and pilot Phase II data reveal 2,000 MG/M2 as the optimal dose of CPI-613 in combination with cytarabine and mitoxantrone for elderly patients with relapsed or refractory AML
-
- Date/Time: Saturday, June 16, 2018 from 17:30 - 19:30
- Type: Poster Presentation
- Location: Stockholmsmässan: Mässvägen 1, 125 80 Älvsjö, Sweden - Poster Area
- Abstract #: PS998
- Link to abstract
- Scheduled Presenters: Timothy S. Pardee, M.D., Ph.D., CMO of Rafael Pharmaceuticals, and Sanjeev Luther, President & CEO of Rafael Pharmaceuticals
INTERVIEW: Dr. Pardee and Sanjeev Luther, Rafael Pharmaceuticals’ CMO, and President and CEO respectively, will be available for media interviews upon request.
CONTACT: Jacob Jonas, jacob.jonas@rafaelpharma.com, for more information.
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. CPI-613 has been granted orphan drug designation for the treatment of pancreatic cancer, AML, myelodysplastic syndromes (MDS), Burkitt’s lymphoma, and T-cell lymphoma. For more information, visit http://www.rafaelpharma.com/ .
